Evolus (EOLS) Net Cash Flow Growth (1y) (2018 - 2026)
Evolus (EOLS) Net Cash Flow Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -1,020.00% |
| 10 | Evolus | 400.25 Mn | 350.45 Mn | 48.90 Mn | 78.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.96% |
| Dec 31, 2025 | 403.42% |
| Sep 30, 2025 | -117.58% |
| Jun 30, 2025 | -97.19% |
| Mar 31, 2025 | -155.84% |
| Dec 31, 2024 | -91.10% |
| Sep 30, 2024 | -196.60% |
| Jun 30, 2024 | -131.50% |
| Mar 31, 2024 | 253.04% |
| Dec 31, 2023 | 305.24% |
| Sep 30, 2023 | 84.60% |
| Jun 30, 2023 | 146.53% |
| Mar 31, 2023 | 43.32% |
| Dec 31, 2022 | -130.37% |
| Sep 30, 2022 | 21.85% |
| Jun 30, 2022 | -120.19% |
| Mar 31, 2022 | 50.89% |
| Dec 31, 2021 | 120.59% |
| Sep 30, 2021 | -143.25% |
| Jun 30, 2021 | 2,345.20% |